(Q38190753)

30 August 2017

1 reference

title

Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults? (English)

1 reference

30 August 2017

author name string

Catherine Weil-Olivier

series ordinal

1

1 reference

30 August 2017

Jacques Gaillat

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

22 February 2014

1 reference

30 August 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

30 August 2017

volume

32

1 reference

30 August 2017

issue

18

1 reference

30 August 2017

page(s)

2022-2026

1 reference

The fundamental link between pneumococcal carriage and disease

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Streptococcus pneumoniae colonisation: the key to pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Pneumococcal colonization in older persons in a nonoutbreak setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Estimating the transmission parameters of pneumococcal carriage in households

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Antibody Responses to Nasopharyngeal Carriage ofStreptococcus pneumoniaein Adults: A Longitudinal Household Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Clonal and Capsular Types Decide Whether Pneumococci Will Act as a Primary or Opportunistic Pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Invasive pneumococcal disease and the potential for prevention by vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

The worldwide impact of the seven-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Pneumococcal serotypes in children in 4 European countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Incidence of invasive pneumococcal disease among elderly people in Southern Catalonia, Spain, 2002–2009: An increase in serotypes not contained in the heptavalent conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

The relationship between pneumococcal serotypes and antibiotic resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Pneumococcal conjugate vaccine is immunogenic in lung fluid of HIV-infected and immunocompetent adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.008

10.1016/J.VACCINE.2014.02.008

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference